Armin Ghobadi, MD, on Blinatumomab Consolidation Post Stem-Cell Transplant for DLBCL

News
Video

Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.

Armin Ghobadi, MD, of Washington University in St. Louis School of Medicine spoke with CancerNetwork about the latest findings from his presentation at ASH regarding blinatumomab (Blincyto) consolidation post autologous hematopoietic stem-cell transplantation in patients with diffuse large B-cell lymphoma (DLBCL).

Transcription:

So, in terms of complete response (CR), 100 days after BEAM (carmustine, etoposide, cytarabine, and melphalan), you expect roughly around 90% of patients to be in complete remission. Here, we had 100% of patients at CR. And if you look at 1 or 2 years later, you expect a disease-free survival around 50% to 60%. So, what we saw here was fitting of what we expect from a BEAM autologous stem-cell transplantation.

The (2 things) that I thought (were) interesting (and) surprising when I saw it was MRD before BEAM and after BEAM. We saw that there were patients that were minimal residual disease-positive that achieved MRD-negative status after blinatumomab. And we found out that CD8/CD4 ratio early on after autologous transplant is actually an indicator of response and durable response to this treatment after BEAM autologous transplant. We saw that even in a small number of a pilot trial.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content